Ovid Therapeutics  logo
Ovid Therapeutics OVID
$ 0.94 -6.26%

Quarterly report 2024-Q3
added 11-12-2024

report update icon

Ovid Therapeutics Income Statement 2011-2024 | OVID

Annual Income Statement Ovid Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

221 M 142 M 186 M 167 M 135 M 78.6 M 161 M - - - - - -

Shares

70.6 M 70.4 M 67.5 M 59.4 M 39.2 M 24.6 M 19.3 M - - - - - -

Historical Prices

3.13 2.01 2.76 2.81 3.6 2.83 8.5 - - - - - -

Net Income

-52.3 M -54.2 M 123 M -81 M -60.5 M -52 M -64.8 M -22.4 M -13.2 M - - - -

Revenue

392 K 1.5 M 208 M 12.6 M - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - - -

Gross Profit

- - - 12.6 K - - - - - - - - -

Operating Income

-59.3 M -55.5 M 124 M -81.4 M -61.4 M -52.9 M -65 M -22.5 M -13.2 M - - - -

Interest Expense

6.94 M 1.38 M -45.7 K - - - - - - - - - -

EBITDA

-58.7 M -55 M 124 M -81.1 M -61.2 M -52.8 M -64.9 M -22.5 M -13.2 M - - - -

Operating Expenses

59.7 M 57.1 M 84.2 M 94 M 61.4 M 52.9 M 65 M - - - - - -

General and Administrative Expenses

31.1 M 32.4 M 37.2 M 30.6 M 19.3 M 19.1 M 15 M 13 M 6.58 M - - - -

All numbers in USD currency

Quarterly Income Statement Ovid Therapeutics

2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

71 M 70.9 M 70.7 M 70.7 M 70.6 M 70.5 M 70.5 M 70.5 M 70.4 M 70.4 M 70.3 M 70.4 M 67.9 M 67.8 M 66.1 M 65.7 M 59.4 M 55.6 M 54.7 M 54.7 M 54.7 M 54.7 M 54.7 M 24.7 M 24.6 M 24.6 M 24.6 M 24.6 M 24.6 M 18.1 M 9.84 M 9.84 M 9.84 M 9.84 M 9.84 M - - - - - - - - - - - - - - - - - - - -

Net Income

-14 M 8.52 M -11.7 M - -11.3 M -12.4 M -13.4 M - -12 M -14.6 M -16.1 M - -11.4 M -15.8 M 176 M - -16.4 M -22.6 M -20 M -17 M -16.6 M -13.1 M -13.8 M -12.9 M -13 M -12.9 M -13.2 M -11 M -9.36 M -10.2 M -34.2 M -7.56 M -5.78 M -5.39 M -3.68 M - - - - - - - - - - - - - - - - - - - -

Revenue

173 K 169 K 148 K - 109 K 75 K 66 K - 11.1 K - 1.45 M - - - 208 M - 6.91 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-13.2 M -20.5 M -17.4 M - -12 M -14.2 M -14.9 M - -12.8 M -14.3 M -16.3 M - -11.7 M -14.3 M 177 M - -16.4 M -23.1 M -20.3 M - -16.8 M -13.3 M -14.1 M - -13.2 M -13.2 M -13.4 M - -9.41 M -10.3 M -34.3 M - -5.81 M -5.42 M - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-780 K 29 M 5.72 M - 776 K 1.76 M 1.54 M - 836 K -284 K 209 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-13.1 M -20.4 M -17.3 M - -11.9 M -14.1 M -14.7 M - -12.7 M -14.2 M -16.2 M - -11.5 M -14.2 M 177 M - -16.2 M -23 M -20.2 M - -16.6 M -13.2 M -14 M - -13.1 M -13.2 M -13.4 M - -9.35 M -10.3 M -34.2 M - -5.79 M -5.4 M 5.9 K - - - - - - - - - - - - - - - - - - - -

Operating Expenses

13.4 M 20.7 M 17.6 M - 12.1 M 14.2 M 15 M - 12.8 M 14.3 M 17.7 M - 11.7 M 14.3 M 31.8 M - 23.3 M 23.1 M 20.3 M 17.3 M 16.8 M 13.3 M 14.1 M 13.1 M 13.2 M 13.2 M 13.4 M 11 M 9.41 M 10.3 M 34.3 M 7.59 M 5.82 M 5.42 M 3.71 M - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

5.54 M 8.1 M 7.17 M - 6.8 M 8.25 M 8.34 M - 7.63 M 8.26 M 9.88 M - 6.76 M 6.63 M 15.6 M - 7.44 M 7.11 M 5.67 M - 5.17 M 4.2 M 4.72 M - 4.63 M 5.09 M 4.96 M - 3.51 M 4.21 M 2.98 M - 3.12 M 3.65 M 2.59 M - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency